Langasog, Rudy S.

HRN: 23-51-55  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/09/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
08/09/2023
08/15/2023
IV
2.25gm
Q8
Acute Pyelonephritis
Waiting Final Action 

Indication:  EmpiricEmpirical Escalation    Type of Infection:  Urinary Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: